Before receiving the study treatments, all patients were asked to assess their baseline degree of pain, level of physical activity, and quality of sleep using three separate 100-mm visual analog scales (VAS), with 0 = minimal (lowest) to 100 = maximal (highest). All patients were instructed to return to the medical center daily during the 2-wk study period to assess the appearance of their cutaneous lesions and to complete the pain, physical activity, and quality of sleep VASs. At the end of the study period, all patients were asked to complete a global assessment questionnaire to evaluate the change in pain, physical activity, and quality of sleep using the VASs.
The assessment of the cutaneous lesions was performed by a blind observer and included: 1) location of the rash; 2) severity of the rash (i.e., number of the lesions in the involved dermatomes) using the following classification system: mild (<25), moderate (25-50), or severe (> 50); 3) the last day that new lesions appeared; 4) the first day without any new lesions; 5) the first day with full crusting of the lesions; and 6) the time to complete healing of the lesions. All patients were contacted at 3-, 6-, and 9-mo intervals to inquire about the presence of pain in a dermatomal pattern corresponding to the level of the acute lesions (i.e., PHN). The severity of the PHN pain was quantified using the 100-mm pain VAS.
Changes in the VAS scores were analyzed by using analysis of variance, with t-tests used to determine intergroup differences and Bonferroni's adjustment for multiple comparisons. Analysis of discrete data was performed using the chi squared test, with P values <0.05 considered statistically significant.
The two treatment groups were similar with respect to demographic characteristics, including the location and severity of the herpetic lesions (Table 1). The PENS group experienced more rapid resolution of the vesicles and complete healing of the lesions (Table 2). The VAS pain scores were consistently lower in the PENS group during the 2-wk observation period (Table 3). On the global assessment questionnaire, the percent decrease in the VAS pain score was 67% in the PENS group compared with 45% in the control group (P < 0.05). The percent improvement in the VAS physical activity and quality of sleep scores (78% vs 60% and 55% vs 37%, respectively) was also greater in the PENS- versus famciclovir-treated patients at the end of the second week. The older patients (>or=to50 yr) were more likely to develop PHN symptoms, and PENS therapy was associated with a decrease in the severity of pain at 3 and 6 mo in this subpopulation (Table 2). However, no differences in PHN symptoms were apparent at the 9-mo follow-up assessment period.
This comparative study suggests that PENS, a novel, nonpharmacologic analgesia technique, may be a viable alternative to antiviral drugs for the treatment of acute herpes zoster lesions. The use of PENS therapy provided pain relief, increased physical activity, and an improved quality of sleep that compared favorably with a standard antiviral therapy. In this preliminary study, PENS therapy was also more effective than famciclovir in preventing PHN-related pain symptoms 3 and 6 mo after resolution of the cutaneous lesions.
Although this study can be criticized because it did not include a placebo (or sham) group, the benefits of antiviral therapy have been firmly established during the acute phase of the illness, and other investigators  have suggested that it would be unethical to include a placebo treatment group. The outcome assessments were blinded because the physician making the assessment was unaware of the treatment that the patients were receiving. Furthermore, the small cutaneous needle puncture sites (0.2 mm) produced by the PENS probes were not apparent to the individual performing the clinical assessments. Nevertheless, future studies should include a sham PENS group that receives the antiviral therapy in combination with the needle probes but without electrical stimulation. Unfortunately, the inclusion of a sham PENS group would not blind the patients because it does not mimic the sensation provided by the electrical stimulation associated with PENS therapy.
The improved physical activity and quality of sleep during the second week of treatment in the PENS group may be secondary to the decrease in the intensity of pain. Although the mechanism of PENS-induced analgesia is not known, it may be related to both neural modulation produced by the electrical stimulus  and an increase in endogenous morphine-like substances (e.g., dynorphins, endorphins, enkephalins) within the central nervous system . Using a rat model for studying electroacupuncture, Chen et al.  reported that an alternating 2-Hz and 15-Hz pattern of electrical stimulation was more effective than a fixed frequency of stimulation at either 2 Hz or 100 Hz in producing experimental analgesia. In a clinical study, Han et al.  reported that low-and high-frequency electrical stimulation resulted in increased cerebrospinal fluid levels of met-enkephalin and dynorphin, respectively. Further studies are clearly needed to determine the precise central nervous system mechanism(s) of PENS-induced analgesia.
Because herpes zoster is caused by a reactivation of the varicella virus residing in the sensory ganglia and spinal cord after the primary viral infection, the beneficial effects of PENS therapy may also be related to electrical stimulation of the involved peripheral sensory nerves. The electrical current can produce localized vasodilation and may stimulate the release of antiinflammatory mediators at the site of injury. Further studies evaluating the efficacy of PENS therapy in immunosuppressed patients would be helpful in understanding the basis for its apparent analgesic and antiinflammatory activity. However, PENS therapy should be evaluated as a supplement to antiviral therapy in this high-risk patient population.
In conclusion, PENS therapy is a unique nonpharmacologic approach to treating immunocompetent patients with acute herpes zoster that compared favorably with standard antiviral drug therapy in this preliminary study.
1. Wood MJ, Organ PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment for the treatment of acute herpes zoster. Am J Med 1988;85:79-83.
2. Beutner KR, Friedman DJ, Forszpaniak C, et al. Valacyclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995;39:1546-53.
3. Stien GE. Pharmacology of new antiherpes agents: famciclovir and valacyclovir. J Am Pharm Assoc 1997;37:157-63.
4. Trying S, Barbarash RA, Nahlik JE, et al. Collaborative famciclovir herpes zoster-study group: famciclovir for the treatment of acute herpes zoster: effects on acute disease and post-herpetic neuralgia. Ann Intern Med 1995;123:89-96.
5. Wood MJ, Johnson RW. A randomized trial of acyclovir for 7 days or 21 days with or without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994;330:896-900.
6. Whitely RJ, Wiess H, Gnann JW Jr, et al. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial-The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Ann Intern Med 1996;125:376-83.
7. De Beneditis G, Besana F, Lorenzetti A, A new topical treatment for acute herpetic neuralgia and post-herpetic neuralgia: the aspirin/diethyl ether mixture. Pain 1992;48:383-90.
8. Nathan PW, Wall PD. Treatment of post-herpetic neuralgia by prolonged electrical stimulation. BMJ 1974;3:645-7.
9. Lewith GT, Field J, Machin D. Acupuncture compared with placebo in postherpetic pain. Pain 1983;17:361-8.
10. Pomerantz BA. Neural mechanisms of acupuncture analgesia. In: Lipton S, ed. Persistent pain. New York: Academic, 1981:271-5.
11. Han JS, Chen XH, Sun SL, et al. Effect of low- and high-frequency TENS on Met-enkephalin-Arg-Phe and dynorphin A immunoreactivity in human lumbar CSF. Pain 1991;47:295-8.
© 1998 International Anesthesia Research Society
12. Chen XH, Guo SF, Chang CG, Han JS. Optimal conditions for eliciting maximal electroacupuncture analgesia with dense- and disperse-mode stimulation. Am J Acupunct 1994;22:47-53.